Regen BioPharma Inc (RGBP)

[ronrooster]

Key points re today's 10 Q.
As of December 18, 2018 , we have not licensed any existing therapies which may be marketed.
On December 17, 2018 Regen Biopharma, Inc.(“Licensor”) , KCL Therapeutics, Inc. (“Assignee”) and Zander Therapeutics, Inc. (“Licensee”) entered into a LICENSE ASSIGNMENT AND CONSENT AGREEMENT whereby, with regards to certain intellectual property which was assigned by Regen Biopharma, Inc.(“Assigned Propertis”) to its wholly owned subsidiary KCL Therapeutics, Inc., Licensor hereby transfers and assigns to Assignee all rights, duties, and obligations of Licensor under the Agreement with respect to the Assigned Properties , and Assignee agrees to assume such duties and obligations thereunder and be bound to the terms of the Agreement with respect thereto.
As of December 18, 2018 there were approximately 467 bagholders of our Common Stock.
On November 28, 2018 the Company issued 10,120,491 Common Shares (“Shares”) in satisfaction of $20,392 of convertible indebtedness.=.002 pps
As of September 30 2018 we had $8,019 in cash on hand and current liabilities of $8,673,511
On October 11, 2018 Regen Biopharma, Inc. amended its Certificate of Incorporation increasing its authorized common shares from 500,000,000 with a par value of 0.0001 to 800,000,000 with a par value of 0.0001